Cargando…

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime

AIMS: Duchenne muscular dystrophy (DMD) is an X‐linked recessive neuromuscular disorder, characterized by significant long‐term cardiac involvement. Dilated cardiomyopathy (DCM) is the main cause of death in DMD, and angiotensin‐converting enzyme inhibitors (ACEi) and beta‐blockers (BB) are first‐li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arcudi, Alessandra, Di Francesco, Marco, Rodolico, Daniele, D'Amario, Domenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715800/ https://www.ncbi.nlm.nih.gov/pubmed/35712811 http://dx.doi.org/10.1002/ehf2.13963

Ejemplares similares

Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology
por: D’Amario, Domenico, et al.
Publicado: (2020)

Comment on: ‘Implantation of a left ventricular assist device to provide long term support for end‐stage Duchenne muscular dystrophy‐associated cardiomyopathy’ by Stoller et al.
por: Adorisio, Rachele, et al.
Publicado: (2018)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19–Negative Patients?
por: D’Amario, Domenico, et al.
Publicado: (2020)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Primetime learning: collaborative and technology-enhanced studying with genuine teacher presence
por: Koskinen, Pekka, et al.
Publicado: (2018)

Primetime for Learning Genes
por: Keifer, Joyce
Publicado: (2017)

Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy
por: Barp, Andrea, et al.
Publicado: (2015)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor
por: Kim, Moo Jun, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
por: Li, Kangbo, et al.
Publicado: (2023)

The Shock Index: is it ready for primetime?
por: Moffat, Brad, et al.
Publicado: (2013)

EUS Gastroenterostomy: Primetime for All?
por: Canakis, Andrew, et al.
Publicado: (2023)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
por: Li, Wanjing, et al.
Publicado: (2022)

Plk1 in Asthma: Ready for Primetime?
por: Tam, John Kit Chung, et al.
Publicado: (2021)

Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis
por: Wang, Yiwen, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
por: Cho, In-Jeong, et al.
Publicado: (2021)

Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect
por: Kim, Heungjo, et al.
Publicado: (2022)

Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation
por: Zhu, Tianyu, et al.
Publicado: (2022)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
por: Kashiwagi, Yusuke, et al.
Publicado: (2023)

Clinical Outcomes in Patients with Ischemic versus Non-Ischemic Cardiomyopathy after Angiotensin-Neprilysin Inhibition Therapy
por: Abumayyaleh, Mohammad, et al.
Publicado: (2021)

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
por: D'Amario, Domenico, et al.
Publicado: (2022)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Neprilysin Inhibitors and Bradykinin
por: Campbell, Duncan J.
Publicado: (2018)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

The appropriate dose of angiotensin‐converting‐enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?
por: Ishida, Junichi, et al.
Publicado: (2015)

eIF4A inhibition: ready for primetime?
por: Cunningham, Tyler A., et al.
Publicado: (2018)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
por: Hsu, Shao-Jung, et al.
Publicado: (2020)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
por: Choi, Hong-Mi, et al.
Publicado: (2020)

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure
por: Sun, Yuxi, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation
por: Dong, Youzheng, et al.
Publicado: (2023)

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
por: Kato, Tomoko, et al.
Publicado: (2023)

Management of pulmonary hypertension associated with valvular heart disease with angiotensin‐receptor neprilysin inhibitor
por: Ali, Hyeon‐Ju Ryoo, et al.
Publicado: (2023)

Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies
por: Adorisio, Rachele, et al.
Publicado: (2020)

The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis
por: Kotak, Sohny, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mgbebjc0gqo9c0u4vcngiolpr8